Overview

Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia

Status:
Recruiting

Trial end date:
2021-09-26

Target enrollment:

Participant gender:

Summary

This is a multicenter, multinational, open label single dose pharmacokinetic (PK) study enrolling at least 32 subjects. The study aims to characterize the pharmacokinetics (PK) of a single intravenous dose of CAZ AVI in pediatric subjects aged 3 months to less than 18 years who are receiving systemic antibiotic therapy for suspected or confirmed nosocomial pneumonia, including ventilator associated pneumonia.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Collaborator:

Allergan

Treatments:

Anti-Bacterial Agents
Avibactam
Avibactam, ceftazidime drug combination
Ceftazidime